GovChime
Notice ID: 4bc68346385746beb186c16abcf28397Award NoticeAwarded

Q403--Home Sleep Study Testing and Scoring Services

Awarded on September 14, 2023. Full description on SAM.gov.

Awarded tounder 36C25523D0058 (source: SAM.gov award notice)• $1.8M

Overview

Posted
September 14, 2023
Notice type
Award Notice
Set-aside
Total Small Business Set-Aside (FAR 19.5)

Notice details

Place of performance
VA Columbia Missouri Healthcare System 800 Hospital Drive, Columbia, 65201
Last updated
Dec 4, 2025
Award date
Sep 14, 2023
Award amount (SAM.gov award notice)
$1.8M

Identifiers

Solicitation number
36C25523Q0575
Notice ID
4bc68346385746beb186c16abcf28397
Award number (PIID)
36C25523D0058

Description

Award Overview

Award Number

36C25523D0058

Award Amount (SAM.gov award notice)

$1.8M

Award Date

Sep 14, 2023

Awardee

Awardee UEI

EQNMU1YE44V7

Awardee CAGE Code

717T9

Original Solicitation

Notice ID: 4bc68346385746beb186c16abcf28397

Posted Date: Sep 14, 2023

Original Response Deadline: Not specified

Task Orders Under This IDV

Top 10 by total obligated

6
  • 36C25525N0442
    SLEEP CARE, INC.
    Department of Veterans AffairsNAICS 621610
    $371.7KSigned Sep 4, 2025
  • 36C25526N0425
    SLEEP CARE, INC.
    Department of Veterans AffairsNAICS 621610
    $371.7KSigned Sep 13, 2026
  • 36C25524N0367
    SLEEP CARE, INC.
    Department of Veterans AffairsNAICS 621610
    $354.0KSigned Aug 1, 2024
  • 36C25523N0487
    SLEEP CARE, INC.
    Department of Veterans AffairsNAICS 621610
    $354.0KSigned Sep 14, 2023
  • 36C25524N0367
    SLEEP CARE, INC.
    Department of Veterans AffairsNAICS 621610
    $326.0KSigned Sep 17, 2026
  • 36C25523N0487
    SLEEP CARE, INC.
    Department of Veterans AffairsNAICS 621610
    $249.9KSigned Mar 4, 2025

More From This Vendor

Top 5 most recent

5
  • 36C25524N0367
    SLEEP CARE, INC.
    Department of Veterans AffairsNAICS 621610
    $326.0KSigned Sep 17, 2026
  • 36C25526N0425
    SLEEP CARE, INC.
    Department of Veterans AffairsNAICS 621610
    $371.7KSigned Sep 13, 2026
  • 36C25025D4480
    SLEEP CARE, INC.
    Department of Veterans AffairsNAICS 621610
    —Signed Jun 25, 2026
  • 36C25026N0575
    SLEEP CARE, INC.
    Department of Veterans AffairsNAICS 621610
    $254.9KSigned May 20, 2026
  • 36C25025N0539
    SLEEP CARE, INC.
    Department of Veterans AffairsNAICS 621610
    $268.2KSigned Dec 15, 2025

Contacts

Documents

No documents available.

Lifecycle

Solicitation:36C25523Q0575
  1. Market Research
  2. Solicitation
  3. Awarded

This opportunity has been awarded.

  1. Market ResearchJun 22, 2023

    Q403--Home Sleep Study Services

    Notice b5c341b97ace4abc8c6443a5c2a607e8 on SAM.gov

  2. 3×
    SolicitationAug 21, 2023

    Q403--Home Sleep Study Services

    Notice 1add0b61295a4ca09b14c53e385ba0e6 on SAM.gov

  3. AwardedCurrentSep 14, 2023

    Q403--Home Sleep Study Testing and Scoring Services

    Notice 4bc68346385746beb186c16abcf28397 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
51%
Combined Synopsis10/28/2026
The Department of Veterans Affairs (VA) is issuing the attached Request for Proposals (RFP) for Medical Disability Examinations – Next Generation (MDE-NG), Solicitation 36C10X27R0001. This is the official solicitation for the MDE-NG requirement. Offerors are responsible for reviewing the complete solicitation, including all attachments, and complying with the requirements, instructions, submission procedures and deadlines stated in the RFP. The solicitation and any amendments issued under this notice supersede any prior draft solicitation materials. Communications and Questions All communications regarding this solicitation must be submitted via email to VAMDENextGenRFP@va.gov. Questions must be submitted in accordance with Section E of the solicitation, including use of the required RFP Questions Template and the deadline stated in the solicitation. Communications specific to this solicitation and its contents should not be directed to MDEO, VBA or other VA personnel. Offerors intending to submit a proposal must also provide the required Proposal Intention in accordance with Section E. Proposals must be submitted using the method and instructions specified in the solicitation and should not be submitted to the solicitation email address. Interested Vendors List VA has enabled the Interested Vendors List (IVL) for this solicitation and has made the list viewable to registered SAM.gov users. VA is making the IVL viewable to facilitate industry awareness and provide prospective prime contractors, subcontractors and teaming partners an opportunity to identify and connect with other interested parties. Vendors that wish to be identified as interested in this solicitation should use the Interested Vendors List functionality available through this SAM.gov notice. Participation in the IVL is voluntary and does not constitute VA endorsement of any vendor or teaming arrangement. Interested parties are encouraged to monitor SAM.gov for amendments and other updates related to this solicitation. *Updates to this notice on 11/10/2026 and 11/17/2026 were to enable the Interested Vendors List (IVL); no new documents are availble.
47%
Solicitation12/17/2026
46%
AwardedOpen
The Department of Veterans Affairs (VA) is issuing the attached Draft Request for Proposals (RFP) for MDE- NG for industry and stakeholder review and feedback. Purpose of the Draft RFP The purpose of releasing this Draft RFP is to provide industry and other interested stakeholders an opportunity to review the Government’s contemplated acquisition approach and solicitation requirements prior to issuance of the final solicitation anticipated for release in November 2026. The Government is seeking constructive feedback to help identify areas that may require clarification, present potential barriers, create performance risk, or otherwise benefit from refinement. The Government encourages respondents to provide specific, actionable feedback regarding the Draft RFP, including the clarity and completeness of the requirements, feasibility of the proposed approach, solicitation terms and conditions, proposal instructions, evaluation methodology, and other matters that respondents believe the Government should consider before finalizing the solicitation. Submission of Feedback All feedback must be submitted using the feedback template, identified as "MDE-NG - DRAFT RFP FEEDBACK, provided with this notice. Respondents should clearly identify the applicable Draft RFP section, page number, paragraph, or other reference associated with each comment or recommendation and provide sufficient rationale to support the proposed change or consideration. Completed feedback templates must be submitted via email to Lindi.Sylvester@va.gov and Zachery.Minns@va.gov no later than 4:00 p.m. Eastern Time (ET) on October 26, 2026. Respondents are requested not to submit feedback through other channels unless specifically directed by the Contracting Officer. The Government may consider feedback received in developing the final solicitation but is under no obligation to incorporate any recommendation or proposed change. Important Notice This Draft RFP is issued for planning and feedback purposes only and does not constitute a solicitation, request for proposals, invitation for bids, or request for quotations. The Government is not requesting proposals in response to this notice and will not accept unsolicited proposals based on the Draft RFP. Responses to this notice are voluntary and shall not be construed as a commitment by the Government to enter into a contract or other agreement. The Government will not reimburse respondents for any costs incurred in reviewing the Draft RFP, preparing feedback, or otherwise responding to this notice. The Government reserves the right to use information received in response to this notice to refine the acquisition strategy, requirements, solicitation, or related acquisition documentation. The Government may elect to address industry and stakeholder feedback through revisions to the final solicitation, amendments or updates to this notice, responses to frequently asked questions, or other means, as appropriate. The Government may not provide individual responses to each comment received. Interested parties are encouraged to monitor SAM.gov for subsequent notices, updates, and the issuance of the final solicitation, if issued.
46%
Pre-Solicitation10/26/2026
DEPARTMENT OF VETERANS AFFAIRS Justification and Approval (J&A) For Other Than Full and Open Competition (>SAT) Acquisition Plan Action ID: 36C245-27-AP-1021 Contracting Activity: Department of Veterans Affairs, VISN 05, NC05, Louis A Johnson VA Medical Center 1 Medical Center Drive Clarksburg, WV 26301 PR# 540-27-1-036-0349 Nature and/or Description of the Action Being Approved: The Louis A Johnson VA Medical Center Pharmacy IV room remains out of service due to ongoing flood remediation and displacement of essential compounding operations. This disruption has left our facility unable to compound hazardous medications needed for Oncology patients, placing timely access to prescribed treatments at risk. A new contract with an external provider to compound and ship these medications to the facility is essential to maintain continuity of care, prevent treatment delays, and sustain Oncology services in the interim of the compounding capabilities being restored. Due to the nature of services, there exists an unusual and compelling urgent need for this highly specialized service. The medical center requires the use of contractor due to the medical center s IV compounding room being down due to flood remediation, upgrades and recertification of the IV room and pharmacists/techs when re-opened. Existing contractual funding has been exhausted, and immediate contractual action is required to ensure continuity of these critical Oncology support services pending award of the follow-on procurement. The estimated value is $500,000.00. Description of Supplies/Services Required to Meet the Agency s Needs: The Clarksburg VA Medical Center requires emergency contract support to compound and ship hazardous medications for oncology patients. Flood remediation has displaced essential pharmacy operations and made the Pharmacy IV room unavailable, preventing on-site preparation. The contractor shall provide all chemotherapy agents, IV tubing, closed-system drug-transfer devices, and other necessary supplies. All hazardous chemotherapy agents shall be aseptically compounded according to patient-specific orders. The Medical Center can identify treatment needs including patient volume and treatment duration only one week in advance. Each week, the Clinical Pharmacy Practitioner will email the contractor a list of medications to be compounded and shipped to the Medical Center for patient treatment. Statutory Authority Permitting Other than Full and Open Competition: ( ) (1) Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements per 41 USC §3304(a)(1) as implemented by RFO 6.103-1; (X ) (2) Unusual and Compelling Urgency per 41 USC §3304(a)(2) as implemented by RFO 6.103-2; ( ) (3) Industrial Mobilization, Engineering, Developmental or Research Capability or Expert Services per 41 USC §3304(a)(3) as implemented by RFO 6.103-3; ( ) (4) International Agreement per 41 USC §3304(a)(4) as implemented by RFO 6.103-4 ( ) (5) Authorized or Required by Statute per 41 USC §3304(a)(5) as implemented by RFO 6.103-5; ( ) (6) National Security per 41 USC §3304(a)(6) as implemented by RFO 6.103-6; ( ) (7) Public Interest per 41 USC §3304(a)(7) as implemented by RFO 6.103-7; Demonstration that the Contractor s Unique Qualifications or Nature of the Acquisition Requires the Use of the Authority Cited Above (applicability of authority): Optum Infusion Services 308 LLC (Optum), is the only one source that is reasonably available because of urgency and who has agreed to continue to provide this highly specialized (hazardous drug compounding) supplies/services for our Oncology patients to ensure there are no unacceptable delays in patient care. Optum maintains sterile compounding operations compliant with applicable regulatory standards, including USP 797 and USP 800, and is capable of providing patient-specific hazardous chemotherapy compounding consistent with the Statement of Work applicable to Louis A Johnson VA Medical Center. Hazardous oncology treatments are clinically time-sensitive, and a transition to an alternate provider would require onboarding and validation activities that may pose a risk of service interruption. Description of Efforts Made to ensure that offers are solicited from as many potential sources as possible (including whether a notice was or will be publicized as required by RFO Part 5 and, if not, which exception under RFO Part 5 applies): In accordance with FAR 5.202(a)(2) The proposed contract action is made under the conditions described in 6.302-2 (or, for purchases conducted using simplified acquisition procedures, if unusual and compelling urgency precludes competition to the maximum extent practicable) and the Government would be seriously injured if the agency complies with the time periods specified in 5.203. The continuing loss of in-house compounding capability creates an immediate requirement for an external provider to prepare and deliver prescribed hazardous medications within clinically required treatment timelines. Failure to establish this support as soon as possible would place oncology treatments at risk of interruption or delay. Due to flood remediation and the resulting loss of in-house hazardous-drug compounding capability, the facility requires immediate external compounding and delivery support to prevent interruption of scheduled Oncology treatments. Delays associated with conducting a full and open competitive acquisition would risk interruption of patient care and adversely affect the Medical Center's ability to provide medically necessary chemotherapy treatments. The Government determined that continuation of services through Optum represents the most immediate and least disruptive means of maintaining continuity of care while acquisition actions for the follow-on requirement are completed. This limited-source approach is based on the unusual and compelling urgency of the requirement rather than a determination that no other provider is capable of performing the services. Market research will continue throughout performance to identify additional qualified sources capable of meeting future requirements. The results of this market research will be documented in the contract file and considered in the acquisition strategy for subsequent procurements. Determination by the CO that the Anticipated Cost to the Government will be Fair and Reasonable: The Independent Government Cost Estimate (IGCE) submitted with the acquisition package represents the Government s best estimate of anticipated costs for hazardous-drug compounding and delivery services. However, the specific chemotherapy medications, dosages, preparation quantities, and treatment frequencies will vary according to individual patients prescribed treatment regimens and clinical needs. Consequently, the exact mix and volume of services cannot be predicted with certainty before contract performance. The final price-reasonableness determination will be based on the pricing established for the services to be provided, rather than an assumption that actual patient utilization will precisely match the estimated quantities. The basis for that determination, including the limitations associated with patient-specific treatment requirements, will be documented in the contract file. Description of the Market Research Conducted and the Results, or a Statement of the Reasons Market Research Was Not Conducted: As described in Section 6 above, market research, in accordance with RFO Part 10, was conducted by synopsis of the proposed acquisition, advising industry of the pending acquisition and soliciting inquiries from interested parties. Any Other Facts Supporting the Use of Other than Full and Open Competition: Optum is currently providing hazardous chemotherapy compounding services to Clarksburg VAMC under IDIQ 36C24526D0059. This existing performance reflects established coordination with the facility and compliance with site-specific requirements. Listing of Sources that Expressed, in Writing, an Interest in the Acquisition: Optum Infusion Services 308 LLC was the only contractor that expressed interest in the acquisition and was available to continue performance within the timeframe necessary to prevent interruption of Oncology treatment services. Given the urgent requirement resulting from the continued outage of the Medical Center's Pharmacy IV room and the need for uninterrupted hazardous-drug compounding services, no other source was identified that could be implemented without transition-related delays that could adversely affect patient care. The Government will continue market research during performance to identify additional qualified sources for future requirements and to maximize competition to the extent practicable. A Statement of the Actions, if any, the Agency May Take to Remove or Overcome any Barriers to Competition before Making subsequent acquisitions for the supplies or services required: Ongoing market research will assess the availability and capabilities of additional providers, including eligible Service-Disabled Veteran-Owned Small Businesses and Veteran-Owned Small Businesses. The assessment will address each potential provider s ability to meet the required compounding, handling, shipping, delivery, and start-date requirements. Requirements Certification: I certify that the requirement outlined in this justification is a Bona Fide Need of the Department of Veterans Affairs and that the supporting data under my cognizance, which are included in the justification, are accurate and complete to the best of my knowledge and belief. Jason Boswell Administrative Officer Clarksburg VAMC 13. Approvals in accordance with the VHAPM Part 806.3 OFOC SOP: Contracting Officer Certification (required): I certify that the foregoing justification is accurate and complete to the best of my knowledge and belief. Mark Smith Contacting Officer NCO5
39%
Special Notice11/24/2026

Additional Details

Solicitation Number

36C25523Q0575

Archive Date

Sep 24, 2023

Office Address

LEAVENWORTH, KS, 66048